New radiotracers such as prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) and 18F-fluciclovine have higher sensitivity and specificity than conventional imaging for detecting new or recurrent prostate cancer [11]. Here, FOLH1 is linked to prostate carcinoma.